Collegium Pharmaceutical: Q3 Earnings Snapshot
Collegium Pharmaceutical (COLL) reported Q3 net income of $21.8M, or 60 cents per share, with adjusted EPS of $1.96. Revenue was $216.3M, exceeding analyst estimates of $1.77 EPS and $215M revenue, according to Zacks.
How this was made

The 30-second read
Why it matters
Earnings beat could trigger short-covering and new buying, especially from investors tracking biotech earnings beats.
Market read
First-report earnings beat for COLL provides a fresh catalyst for short-term trading.
What to watch
Guidance outlook and pipeline updates were not disclosed.
Background
Collegium Pharmaceutical (COLL) is a specialty pharma company focused on rare diseases.
Ticker impact
Collegium Pharmaceutical reported Q3 net income of $21.8M, EPS $0.60 and revenue $216.3M, both beating Zacks estimates.
likely upside as investors price in the earnings beat.
The beat exceeds consensus estimates, which typically drives short-term buying pressure.
Market effects
Positive earnings may lift other specialty pharma peers.
Limited to US biotech/ pharma sector.
Modest, confined to niche biotech investors.
Counterpoint
Beat may be priced in quickly, limiting upside.
Key entities
- companyCollegium Pharmaceutical Inc.
Specialty pharmaceutical firm reporting Q3 results.


